EUVIMEDEUVIMED entdecken
Multizentrische Studie

Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan

Koji Yokoyama iD, Yoko Yamamoto, Ryusuke Nambu iD, Shin-Ichiro Hagiwara, Daiki Abukawa, Tatsuki Mizuochi iD, Takahiro Kudo iD, Tomomitsu Sado, Naomi Iwata, Takashi Ishige, Itaru Iwama iD, Hideki Kumagai und 2 weitere

Journal of Gastroenterology and Hepatology · 2023

DOI: 10.1111/jgh.16246 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Koji Yokoyama und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Jichi Medical University School of Medicine, Tochigi, Japan. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Biological Products. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: Japanese Society for Pediatric Inflammatory Bowel Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vedolizumab (VDZ) is a humanized monoclonal antibody that binds to α4β7 integrin expressed in T‐lymphocytes and is gut selective. Few studies have evaluated the safety and efficacy of VDZ in pediatric ulcerative colitis (UC) patients, especially from Asia.

Methods

A longitudinal multicenter retrospective study was conducted at 10 Japanese tertiary medical institutions. Patients aged ≤18 years old who received VDZ for UC between January 2019 and July 2021 were enrolled. Information on the clinical characteristics, prior/concomitant treatment, and safety during the observation period was collected.

Results

The data obtained from 48 patients (males, n = 30; females, n = 18) were analyzed. The median age at VDZ induction was 14 (range 4–18) years old. VDZ was indicated in 73% of patients as switching from previous biologics due to primary failure, loss of response, and adverse events (AEs) and was the first biologic in 27%. Remission was achieved or maintained at weeks 14, 30, and 54 in 79.2%, 75.0%, and 65.8% of patients, respectively. There were no significant differences between the number of previous biologics exposures and VDZ effectiveness. The hematocrit, serum albumin concentrations, and erythrocyte sedimentation rate (ESR) at baseline differed significantly by VDZ effectiveness. Nine AEs, including infusion reaction, were noted in seven (14.3%) patients. There were no severe AEs related to VDZ administration.

Conclusions

VDZ was safe and effective in children with UC. The hematocrit, albumin, and ESR at VDZ initiation might be predictors for VDZ effectiveness. VDZ may be an important option for pediatric patients and can be used as an alternative to immunomodulators.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeBiological ProductsMaleFemaleHumansChildChild, PreschoolAdolescentRetrospective StudiesJapanGastrointestinal AgentsBiological FactorsTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

biologicschildreninflammatory bowel diseaseulcerative colitisvedolizumab

Substanzen

Gastrointestinal AgentsBiological FactorsBiological ProductsvedolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pediatrics, Jichi Medical University School of Medicine, Tochigi, Japan.
  • Division of Gastroenterology, National Center for Child Health and Development, Tokyo, Japan.
  • Division of Gastroenterology and Hepatology, Saitama Children's Medical Center, Saitama, Japan.
  • Department of Gastroenterology and Endocrinology, Osaka Women's and Children's Hospital, Osaka, Japan.
  • Department of Gastroenterology and Hepatology, Miyagi Children's Hospital, Sendai, Japan.
  • Department of Pediatrics and Child Health, Kurume University School of Medicine, Kurume, Japan.

ORCID-Profile: Koji Yokoyama, Ryusuke Nambu, Tatsuki Mizuochi, Takahiro Kudo, Itaru Iwama, Katsuhiro Arai

Förderung

  • Japanese Society for Pediatric Inflammatory Bowel Disease

Zitieren

APA

Yokoyama, K., Yamamoto, Y., Nambu, R., Hagiwara, S. I., Abukawa, D., Mizuochi, T., Kudo, T., Sado, T., Iwata, N., Ishige, T., Iwama, I., Kumagai, H., Arai, K., & Shimizu, T. (2023). Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16246

Vancouver

Yokoyama K, Yamamoto Y, Nambu R, Hagiwara SI, Abukawa D, Mizuochi T, et al. Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16246

BibTeX
@article{Yokoyama2023,
  author = {Yokoyama, Koji and Yamamoto, Yoko and Nambu, Ryusuke and Hagiwara, Shin-Ichiro and Abukawa, Daiki and Mizuochi, Tatsuki and Kudo, Takahiro and Sado, Tomomitsu and Iwata, Naomi and Ishige, Takashi and Iwama, Itaru and Kumagai, Hideki and Arai, Katsuhiro and Shimizu, Toshiaki},
  title = {Safety and efficacy of vedolizumab in pediatric patients with ulcerative colitis: multicenter study in Japan},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2023},
  doi = {10.1111/jgh.16246}
}
Kostenlos starten →